v3.25.3
Equity-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Mar. 31, 2025
Aug. 20, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense $ 15,802 $ 14,904 $ 45,451 $ 41,213    
Research and Development Expense            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense 8,360 7,604 23,943 20,944    
General and Administrative            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense 7,442 7,300 21,508 20,269    
Employee Stock Option            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Intrinsic value of stock options exercised $ 8,600 $ 10,400 $ 16,000 $ 19,000    
Weighted-average fair value of options granted $ 33.67 $ 29.36 $ 22.73 $ 26.03    
Unrecognized stock-based compensation expense $ 73,500   $ 73,500      
Unrecognized compensation cost, recognition period     2 years 1 month 6 days      
Equity-based compensation expense 12,545 $ 12,382 $ 36,506 $ 34,985    
Employee Stock Option | Research and Development Expense            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense 5,919 5,950 17,615 16,925    
Employee Stock Option | General and Administrative            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense 6,626 $ 6,432 18,891 $ 18,060    
Restricted Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Unrecognized stock-based compensation expense $ 31,300   $ 31,300      
Unrecognized compensation cost, recognition period     2 years 9 months 18 days      
Granted 243,950 152,288 763,050 396,272    
Equity-based compensation expense $ 2,800 $ 2,300 $ 8,000 $ 5,600    
Restricted Stock | Research and Development Expense            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense 2,300 1,500 5,800 3,600    
Restricted Stock | General and Administrative            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Equity-based compensation expense $ 500 $ 800 $ 2,200 $ 2,000    
2020 Plan            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Number of shares authorized for issuance under plan           4,457,370
Maximum number of shares to be issued, percentage     4.00%      
Shares remaining available for future grants 4,138,724   4,138,724      
Performance stock options vesting         40.00%  
Second clinical milestone vesting percentage         40.00%  
Third clinical milestone vesting percentage         20.00%  
Granted     88,000      
Option Indexed to Issuer's Equity, Strike Price     $ 30.17      
Performance stock options outstanding 88,000   88,000      
2020 Plan | Restricted Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Granted 0 0 285,723 0    
2020 Plan | Performance Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Performance stock options vesting         40.00%  
Second clinical milestone vesting percentage         40.00%  
Third clinical milestone vesting percentage         20.00%  
Option Indexed to Issuer's Equity, Strike Price     $ 30.17      
2020 Plan | Minimum [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Performance stock options range         0.00%  
2020 Plan | Minimum [Member] | Performance Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Performance stock options range         0.00%  
2020 Plan | Maximum [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Performance stock options range         100.00%  
2020 Plan | Maximum [Member] | Performance Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Performance stock options range         100.00%  
2020 ESPP            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Number of shares authorized for issuance under plan           445,653
Shares remaining available for future grants 2,318,998   2,318,998      
Share-based compensation, description     The 2020 ESPP initially reserved and authorized the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1% of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP      
2020 ESPP | Lesser of Potential Outcome 1            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Maximum number of shares to be issued, percentage     1.00%      
Number of additional shares authorized     438,898      
2018 Plan | Restricted Stock            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Granted     1,048,773